Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium: An Age-Stratified Study

• DOI: 10.1007/s40122-023-00490-5
• Publication Date: 2023-03-26T20:34:51Z
• Authors: Shiting Yan; Hao Wu; Yanlong Yu; Ning Li; Leyang Yu; Ying Wang; Hu Li; Dongsheng Zhang; Zhuan Zhang
• Keywords: ED50

Rocuronium intravenous pain is common in induction of general anesthesia. The aim our study was to determine the median effective dose (ED50) prophylactic remifentanil for prevention rocuronium injection and explore effect age on ED50.Eighty-nine adult patients undergoing elective anesthesia, ASA I or II, regardless gender weight, were stratified according age: group R1 18-44 years, R2 45-59 R3 60-80 years. initial before set at 1 μg/kg lean body weight (LBW). doses adjusted degree using Dixon sequential method, with a ratio 1.1 between adjacent doses. Injection graded, occurrence adverse reactions recorded. ED50 95% confidence intervals (CIs) calculated Dixon-Massey formula. Patients asked whether they recalled feeling any post-anesthesia care unit (PACU).The (95% CIs) 1.266 (1.186-1.351 μg/kg), 1.188 (1.065-1.324 1.070 (1.014-1.129 μg/kg) LBW R1, R2, R3, respectively. No occurred group. In PACU, 84.6, 86.7, 85.7% who experienced had memories respectively.Prophylactic can prevent pain, its decreases age, (18-44 years), (45-59 (60-80 respectively.ClinicalTrials.gov: NCT05217238 (registration date 18 Dec 2021).